584222

Tetrahydrouridine

Potent competitive inhibitor of cytidine deaminase. Also available as a 100 mM solution in H2O.

• Synonyme(s) : Tetrahydrouridine
• Formule empirique (notation de Hill): C₉H₁₆N₂O₆
• Numéro CAS: 18771-50-1
• Poids moléculaire : 248.23
• Code UNSPSC : 12352208
• Nomenclature NACRES : NA.51

Propriétés

• Niveau de qualité: 100
• Pureté: ≥90% (TLC)
• Forme: solid
• Fabricant/nom de marque: Calbiochem^®
• Conditions de stockage: OK to freeze; desiccated (hygroscopic); protect from light
• Couleur: white to off-white
• Solubilité: water: 200 mg/mL
• Conditions d'expédition: wet ice
• Température de stockage: −20°C
• InChI: 1S/C9H16N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h4-8,12-15H,1-3H2,(H,10,16)/t4-,5?,6-,7-,8-/m1/s1
• Clé InChI: UCKYOOZPSJFJIZ-XVKVHKPRSA-N

Description

Description générale

A potent competitive inhibitor of cytidine deaminase. Used in combination with cytosine arabinoside (Ara-C) to assess the anti-leukemic activity and anti-tumor activity of Ara-C in in vitro studies.

Potent competitive inhibitor of cytidine deaminase. Also available as a 100 mM solution in H₂O(Cat. No. 584223).

Application

• Oncotherapy resistance explained by Darwinian and Lamarckian models.: This research explores the mechanisms of oncotherapy resistance, combining Darwinian and Lamarckian models to provide a comprehensive understanding. The study highlights the role of Tetrahydrouridine in modulating therapy resistance pathways in cancer treatment (Saunthararajah et al., 2024).


• Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy.: This study investigates the potential of using Tetrahydrouridine in non-cytotoxic therapies for small cell lung cancers, focusing on neuroendocrine lineage commitment and its implications for treatment efficacy (Biswas et al., 2023).


• In Vitro Interaction of Tetrahydrouridine with Key Human Nucleoside Transporters.: This study explores how Tetrahydrouridine interacts with human nucleoside transporters, shedding light on its mechanisms of action and potential as a therapeutic agent in biochemistry and pharmacology (Säll et al., 2023).


• Mycoplasma infection of cancer cells enhances anti-tumor effect of oxidized methylcytidines.: This research investigates how mycoplasma infection enhances the anti-tumor effects of oxidized methylcytidines, with Tetrahydrouridine playing a crucial role in the observed therapeutic outcomes (Pang et al., 2023).

Conditionnement

Packaged under inert gas

Avertissement

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot, purge with inert gas, and freeze (-20°C). Aqueous stock solutions (at neutral or basic pH) are stable for up to 3 months at -20°C.

Autres remarques

Yusa, K., et al. 1995. Biochem. Biophys. Res. Commun. 206, 486.
Bouffard, D.Y., et al. 1993. Biochem Pharmacol.45, 1857.
Laliberte, J., et al. 1992. Cancer Chemotherap. Pharmacol.30, 7.
Riva, C., et al. 1992. Chemotherapy38, 358.
Yusa, K., et al. 1992. J. Biol. Chem. 267, 16848.
Hanze, A.R. 1967. J. Am. Chem. Soc.89, 6720.

Informations légales

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable